Harpoon Therapeutics TriTAC Platform Driving Trispecific Antibodies Research Landscape
Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global Market Analysis
- Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion
- US To Dominate Trispecific Antibodies Market: >70%
- Market and Drug Sales Insight 2024 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Global Trispecific Antibody Market Opportunity & Clinical Trials Insight 2028 Report:
In last few years, therapeutic antibodies have emerged out to be mainstream approach in the management of cancer. The progress in the field of science and protein engineering methods has allowed further development of more efficient trispecific antibodies. These are novel class which can bind to three different epitopes or antigens simultaneously, thus depicting more specificity and efficacy in the management of various diseases, including cancer. Although no trispecific antibody has entered the market yet, but the large number of ongoing clinical trials in the market suggests that these modalities will emerge as one of the major breakthrough in cancer therapy market.
Harpoon Therapeutics is one of the leading pharmaceutical giants in trispecific antibody market. The company has developed wide range of trispecific T cell engagers by utilizing its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform. HPN328 developed by company is an investigational DLL3 targeting TriTAC which is being evaluated in phase-I/II clinical for the management of patients with small cell lung cancer, neuroendocrine and other DLL3-associated tumors. The preliminary results from the trial suggest that HPN328 was well tolerated and was not associated with any treatment related adverse events. In addition to this, the company is also developing HPN217 in collaboration with AbbVie for the management of multiple myeloma patients.
The promising preclinical and preliminary response of trispecific antibodies has also gained interest from pharmaceutical giants to grant special designation to expedite their research and development. For instance in March 2022, US FDA granted Orphan Drug designation to HPN328 for the treatment of patients with small cell lung cancer. US FDA orphan drug designation program is associated with several benefits such as research grants, tax benefits, assistance for clinical trials and other protocols which aid in early approval of the drug. In addition to this, it also grants 7 years orphan exclusivity for the approved drugs. Moreover, US FDA also granted Fast Track designation to HPN217 for the treatment of patients with relapsed, refractory multiple myeloma.
Although trispecific antibodies have shown significant improvement in clinical outcome of cancer patients, these are associated with several limitations. Tumor heterogeneity and development of resistance are the major challenges to current trispecific antibodies. One potential solution to increase the efficacy of trispecific antibodies; researchers are now practicing combinational therapy which combines trispecific antibodies with other cancer targeting modalities or with one another. Recently in 2022, Harpoon Therapeutics entered into research collaboration and clinical supply agreement with Roche to evaluate the efficacy of HPN328 in combination with atezolizumab on solid tumors.
The global trispecific antibody market is highly competitive in nature, with major players focused on adoption of various strategies such as product innovation, product launches, and approvals, research and development investment for advancement in trispecific antibody market. The pipeline for novel trispecific antibodies is highly competitive and consists of several potential candidates including GTB3550, GTB4550, HPN217, NM21 -1480, SAR443216, and others. The key players in the market are GT Biopharma, Numab, Harpoon Therapeutics, Sanofi, Marogenics, and others.
As per our report findings, the global trispecific antibody market will be mainly driven by the rapid increase in the geriatric population which possesses significant risk of developing cancer. Moreover, the unavailability of effectively curing cancer drugs also demands for the development of targeted therapy which will also boost the market. Keeping in mind the high adoption rates of novel cancer therapies, it is expected that US will dominate the market for next 5-7 years. In addition to this, high awareness among the population, presence of large biopharmaceutical sector will also propel the growth of market in this region.
Contact:
Neeraj Chawla
Research Head
+91-9810410366